PASylation: a biological alternative to PEGylation for extending the plasma half-life of pharmaceutically active proteins
about
Widening and Elaboration of Consecutive Research into Therapeutic Antioxidant Enzyme DerivativesFusion Proteins for Half-Life Extension of Biologics as a Strategy to Make BiobettersAutomated solid-phase peptide synthesis to obtain therapeutic peptidesEngineering of temperature- and light-switchable Cas9 variantsAnticalins: exploiting a non-Ig scaffold with hypervariable loops for the engineering of binding proteins.Beyond new chemical entities: advancing drug development based on functional versatility of antibodiesThe intrinsic disorder alphabet. III. Dual personality of serine.Nanoparticle Probes for the Detection of Cancer Biomarkers, Cells, and Tissues by FluorescenceEnhanced in vivo efficacy of a type I interferon superagonist with extended plasma half-life in a mouse model of multiple sclerosisPAS-cal: a generic recombinant peptide calibration standard for mass spectrometry.PAS-cal: A repetitive peptide sequence calibration standard for MALDI mass spectrometry.High contrast tumor imaging with radio-labeled antibody Fab fragments tailored for optimized pharmacokinetics via PASylation.Protein-polymer conjugation-moving beyond PEGylation.Titratable Avidity Reduction Enhances Affinity Discrimination in Mammalian Cellular Selections of Yeast-Displayed Ligands.Discovery and Characterization of a Novel CD4-Binding Adnectin with Potent Anti-HIV Activity.Genetic fusion of human FGF21 to a synthetic polypeptide improves pharmacokinetics and pharmacodynamics in a mouse model of obesity.Fab-dsFv: A bispecific antibody format with extended serum half-life through albumin binding.Bridging the species divide: transgenic mice humanized for type-I interferon response.Control of Hepatitis B Virus by CytokinesProtein-polymer therapeutics: a macromolecular perspective.Future strategies for the discovery of therapeutic aptamers.Half-life extended biotherapeutics.Geometry and expression enhance enrichment of functional yeast-displayed ligands via cell panning.Designing disorder: Tales of the unexpected tails.Self-assembling peptide-based building blocks in medical applications.Design and engineering of deimmunized biotherapeutics.Biology of anti-TNF agents in immune-mediated inflammatory diseases: therapeutic implications.Materials and methods for delivery of biological drugs.Half-Life Extension of Biopharmaceuticals using Chemical Methods: Alternatives to PEGylation.A Helping Hand to Overcome Solubility Challenges in Chemical Protein Synthesis.Chemically synthesized dicarba H2 relaxin analogues retain strong RXFP1 receptor activity but show an unexpected loss of in vitro serum stability.pH-Responsive Mesoporous Silica and Carbon Nanoparticles for Drug Delivery.Nanoparticle-macrophage interactions: A balance between clearance and cell-specific targeting.Anti-PEG antibodies in the clinic: Current issues and beyond PEGylation.The polypeptide biophysics of proline/alanine-rich sequences (PAS): Recombinant biopolymers with PEG-like properties.Development of a novel nano-sized anti-VEGFA nanobody with enhanced physicochemical and pharmacokinetic properties.Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation.Selective Nanoparticle Targeting of the Renal Tubules.Molecular Design, Expression and Evaluation of PASylated Human Recombinant Erythropoietin with Enhanced Functional Properties.Treatment of diet-induced lipodystrophic C57BL/6J mice with long-acting PASylated leptin normalises insulin sensitivity and hepatic steatosis by promoting lipid utilisation.
P2860
Q26752431-55EBF5DC-0B7F-4CB1-9FB6-9EEBFF4D8AFFQ26801319-51040212-A98D-41C9-880B-D95EA3E86E10Q27001623-84266BC2-3BDA-41EC-8522-305A65A8AB3AQ29114084-187CF331-5F9D-49CB-ACE2-5D0D1156E1FFQ30153481-08CF0546-666D-4CF3-92EA-D16D79DBA380Q30386064-7F0FB04A-6E68-4683-81B3-849E4005D0B0Q30399038-59DF5AE2-3799-47F2-9DE1-F03FAB59FD22Q33759991-AF3D5ED4-AD98-4B81-9B74-D401488BA04FQ34355672-279A09BB-9DC2-4321-A437-617DCFDD26EFQ35175082-315E8E9F-0B6B-4282-88BD-CFAF519A442DQ35229089-769E37B2-B0D3-4147-9F5C-A861B63A22F5Q36211450-60B86E7E-2C57-4549-AE47-88C27FCBE49FQ36220152-AC77382B-4964-4440-ABCD-B1A86B0F5FFAQ36316025-A4FBAC57-C7DE-4947-911F-852CDDB0FD03Q36393594-C69C1184-D843-4374-9F7C-B3357AB4427CQ37034745-78B766D7-817D-43E7-9190-86321F5E5B7AQ37327316-F3310FED-D390-4981-B04E-F8632CE12E88Q37458573-ADD17A62-94BB-4481-AA89-60C8DD7D2D36Q37628224-72CF8B48-0727-4E42-8D54-E503802F695BQ38555997-21AB602C-810A-44E9-883B-B67A5787E74EQ38748406-67E7CCB9-012C-49AB-8A4F-3DF218670C8EQ38770067-929B54C1-C46C-4853-9F27-BF50C25C6CDDQ38773272-AE71EE35-EAE2-4074-8E23-6C27ADEECE25Q38779715-7A236514-AEF1-4B0D-9A7E-E9167E4197E9Q38830346-CE4638C2-853E-4D4F-B858-C45EC1BF5BB0Q38870681-70B2BB5F-D759-477B-B900-F6C2ABE8604FQ38979811-C9047C33-4CEF-494E-A44C-AFB6473D0259Q38987392-275BFD55-03DC-4538-9FAD-259AAF513398Q38989309-71A88635-5F1C-4635-A9FB-8386FC6BF521Q40092320-CE8EB14E-ECC2-4EFF-B877-44C0CDF6B0E5Q40541284-142E886E-B149-4A8E-830F-18AB9A0E3A52Q41512962-71946E1B-D74F-4F52-8F5A-6BABC8ED5847Q42381383-0B54D87F-371E-4408-8804-347E50940F1FQ47102857-8DD2668D-0824-4938-B442-F2114C80E8E5Q47596433-A9CE1DBF-A39B-4C7F-A3AB-9DF07C2B081BQ47753474-0DEA290B-F51F-4811-90A7-3E58F64075A3Q48114152-8B4C342E-E4A9-44A7-96A3-35ECAC27AD5EQ48602509-E1A383BB-CF30-4E5C-ABF6-8D23B4F22958Q50216954-A24CD90A-C2D8-4C42-ABF0-99539342C272Q50801472-3EB55B0C-7BA5-4B38-AF72-ED8CE6DD33E3
P2860
PASylation: a biological alternative to PEGylation for extending the plasma half-life of pharmaceutically active proteins
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
PASylation: a biological alter ...... armaceutically active proteins
@en
PASylation: a biological alter ...... rmaceutically active proteins.
@nl
type
label
PASylation: a biological alter ...... armaceutically active proteins
@en
PASylation: a biological alter ...... rmaceutically active proteins.
@nl
prefLabel
PASylation: a biological alter ...... armaceutically active proteins
@en
PASylation: a biological alter ...... rmaceutically active proteins.
@nl
P2093
P2860
P50
P356
P1476
PASylation: a biological alter ...... armaceutically active proteins
@en
P2093
Claudia Börger
Ina Theobald
Klaus Wachinger
Sigrid Kisling
Uli Binder
P2860
P304
P356
10.1093/PROTEIN/GZT023
P577
2013-06-10T00:00:00Z